Genomic Health (FRA:G7H) Other Gross PPE : €87.7 Mil (As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Genomic Health Other Gross PPE?

Genomic Health's Other Gross PPE for the quarter that ended in Sep. 2019 was €87.7 Mil.

Genomic Health's quarterly Other Gross PPE increased from Mar. 2019 (€82.5 Mil) to Jun. 2019 (€84.1 Mil) and increased from Jun. 2019 (€84.1 Mil) to Sep. 2019 (€87.7 Mil).

Genomic Health's annual Other Gross PPE increased from Dec. 2016 (€19.7 Mil) to Dec. 2017 (€24.6 Mil) and increased from Dec. 2017 (€24.6 Mil) to Dec. 2018 (€26.3 Mil).

Genomic Health Other Gross PPE Historical Data

The historical data trend for Genomic Health's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Health Other Gross PPE Chart

Genomic Health Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Other Gross PPE

Get a 7-Day Free Trial

14.52

18.98

19.68

24.61

26.33

Genomic Health Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Other Gross PPE	Get a 7-Day Free Trial															34.11	26.33	82.49	84.10	87.69

Genomic Health Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Genomic Health (FRA:G7H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Health Inc (FRA:G7H) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Penobscot Drive, Redwood City, CA, USA, 94063

Website

http://www.genomichealth.com

Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Genomic Health (FRA:G7H) Headlines

No Headlines